NCT02158507View on ClinicalTrials.gov

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions
Metastatic Triple Negative Breast Cancer
Interventions
DRUG

Combination of Veliparib + Lapatinib

Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (2)

GlaxoSmithKline
AbbVie
All Listed Sponsors
collaborator

Breast Cancer Research Foundation of Alabama

UNKNOWN

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

AbbVie

INDUSTRY

lead

University of Alabama at Birmingham

OTHER